Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex.

Jochems C, Tritsch SR, Knudson KM, Gameiro SR, Rumfield CS, Pellom ST, Morillon YM, Newman R, Marcus W, Szeto C, Rabizadeh S, Wong HC, Soon-Shiong P, Schlom J.

Oncoimmunology. 2018 Nov 27;8(2):e1532764. doi: 10.1080/2162402X.2018.1532764. eCollection 2019.

2.

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.

Hicks KC, Fantini M, Donahue RN, Schwab A, Knudson KM, Tritsch SR, Jochems C, Clavijo PE, Allen CT, Hodge JW, Tsang KY, Schlom J, Gameiro SR.

Oncoimmunology. 2018 Jul 30;7(11):e1466018. doi: 10.1080/2162402X.2018.1466018. eCollection 2018.

3.

First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.

Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marté JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL.

Clin Cancer Res. 2019 Jan 1;25(1):99-109. doi: 10.1158/1078-0432.CCR-18-1512. Epub 2018 Aug 21.

PMID:
30131389
4.

An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.

Fujii R, Jochems C, Tritsch SR, Wong HC, Schlom J, Hodge JW.

Cancer Immunol Immunother. 2018 Apr;67(4):675-689. doi: 10.1007/s00262-018-2121-4. Epub 2018 Feb 1.

5.

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).

Jochems C, Tritsch SR, Pellom ST, Su Z, Soon-Shiong P, Wong HC, Gulley JL, Schlom J.

Oncotarget. 2017 Sep 8;8(43):75217-75231. doi: 10.18632/oncotarget.20680. eCollection 2017 Sep 26.

6.

ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.

Jochems C, Hodge JW, Fantini M, Tsang KY, Vandeveer AJ, Gulley JL, Schlom J.

Int J Cancer. 2017 Aug 1;141(3):583-593. doi: 10.1002/ijc.30767. Epub 2017 May 19.

7.

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.

Donahue RN, Lepone LM, Grenga I, Jochems C, Fantini M, Madan RA, Heery CR, Gulley JL, Schlom J.

J Immunother Cancer. 2017 Feb 21;5:20. doi: 10.1186/s40425-017-0220-y. eCollection 2017.

8.

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.

Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM 2nd, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J.

Oncotarget. 2016 Dec 27;7(52):86359-86373. doi: 10.18632/oncotarget.13411.

9.

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.

Jochems C, Fantini M, Fernando RI, Kwilas AR, Donahue RN, Lepone LM, Grenga I, Kim YS, Brechbiel MW, Gulley JL, Madan RA, Heery CR, Hodge JW, Newton R, Schlom J, Tsang KY.

Oncotarget. 2016 Jun 21;7(25):37762-37772. doi: 10.18632/oncotarget.9326.

10.

A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.

Duggan MC, Jochems C, Donahue RN, Richards J, Karpa V, Foust E, Paul B, Brooks T, Tridandapani S, Olencki T, Pan X, Lesinski GB, Schlom J, Carson Iii WE.

Cancer Immunol Immunother. 2016 Nov;65(11):1353-1364. Epub 2016 Aug 31.

11.

The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy.

Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J.

Oncoimmunology. 2016 May 19;5(7):e1188243. doi: 10.1080/2162402X.2016.1188243. eCollection 2016 Jul.

12.

Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial.

Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, Steinberg SM, Marté JL, Chen CC, Grenga I, Donahue RN, Jochems C, Dahut WL, Schlom J, Gulley JL.

Oncotarget. 2016 Oct 18;7(42):69014-69023. doi: 10.18632/oncotarget.10883.

13.

Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Marté JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio LR, Schlom J, Gulley JL.

JAMA Oncol. 2015 Nov;1(8):1087-95. doi: 10.1001/jamaoncol.2015.2736. Erratum in: JAMA Oncol. 2015 Nov;1(8):1171-2.

14.

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J.

Cancer Immunol Res. 2015 Oct;3(10):1148-1157. doi: 10.1158/2326-6066.CIR-15-0059. Epub 2015 May 26.

15.

Possible role of lymphocytes in glucocorticoid-induced increase in trabecular bone mineral density.

Grahnemo L, Jochems C, Andersson A, Engdahl C, Ohlsson C, Islander U, Carlsten H.

J Endocrinol. 2015 Jan;224(1):97-108. doi: 10.1530/JOE-14-0508. Epub 2014 Oct 30.

16.

Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis.

Tucker JA, Jochems C, Boyerinas B, Fallon J, Greiner JW, Palena C, Rodell TC, Schlom J, Tsang KY.

Cancer Immunol Immunother. 2014 Dec;63(12):1307-17. doi: 10.1007/s00262-014-1603-2. Epub 2014 Sep 4.

17.

Therapeutic cancer vaccines.

Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL.

Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. Review.

18.

Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.

Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, Jochems C, Tsang KY, Cheng Q, Lyerly HK, Schlom J, Guadagni F.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju054. doi: 10.1093/jnci/dju054.

19.

Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.

Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J.

Cancer Immunol Res. 2014 Feb;2(2):133-41. doi: 10.1158/2326-6066.CIR-13-0108. Epub 2013 Nov 4.

20.

Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy.

Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, Gulley JL, Schlom J, Farsaci B.

J Immunol. 2014 Mar 15;192(6):2622-33. doi: 10.4049/jimmunol.1301369. Epub 2014 Feb 10.

21.

A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.

Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.

Cancer Immunol Immunother. 2014 Apr;63(4):407-18. doi: 10.1007/s00262-014-1524-0. Epub 2014 Feb 11.

22.

Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.

Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, Madan RA, Gulley JL, Schlom J.

Int J Cancer. 2014 Aug 15;135(4):862-70. doi: 10.1002/ijc.28743. Epub 2014 Feb 22.

23.

Effects of conventional therapeutic interventions on the number and function of regulatory T cells.

Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F.

Oncoimmunology. 2013 Oct 1;2(10):e27025.

24.

Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.

Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA.

Cancer Immunol Immunother. 2014 Mar;63(3):225-34. doi: 10.1007/s00262-013-1505-8. Epub 2013 Dec 7.

25.

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.

Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang KY.

Cancer Immunol Immunother. 2014 Feb;63(2):161-74. Epub 2013 Nov 15.

26.

Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.

Madan RA, Tsang KY, Bilusic M, Vergati M, Poole DJ, Jochems C, Tucker JA, Schlom J, Giaccone G, Gulley JL.

Oncologist. 2013;18(7):821-2. doi: 10.1634/theoncologist.2013-0199. Epub 2013 Jul 11.

27.

Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.

Huang J, Jochems C, Anderson AM, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.

J Immunol. 2013 Jun 15;190(12):6250-8. doi: 10.4049/jimmunol.1300022. Epub 2013 May 15.

28.

The role of soluble CD40L in immunosuppression.

Schlom J, Jochems C, Gulley JL, Huang J.

Oncoimmunology. 2013 Jan 1;2(1):e22546.

29.

Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.

Huen NY, Pang AL, Tucker JA, Lee TL, Vergati M, Jochems C, Intrivici C, Cereda V, Chan WY, Rennert OM, Madan RA, Gulley JL, Schlom J, Tsang KY.

Int J Cancer. 2013 Jul 15;133(2):373-82. doi: 10.1002/ijc.28026. Epub 2013 Feb 12.

30.

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J.

Blood. 2012 Oct 11;120(15):3030-8. doi: 10.1182/blood-2012-05-427799. Epub 2012 Aug 28.

31.

Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.

Tucker JA, Jochems C, Gulley JL, Schlom J, Tsang KY.

Cancers (Basel). 2012 Dec 11;4(4):1333-48. doi: 10.3390/cancers4041333.

32.

A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.

Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.

Clin Cancer Res. 2011 Nov 15;17(22):7164-73. doi: 10.1158/1078-0432.CCR-11-0649. Epub 2011 Nov 8.

33.

Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis.

Islander U, Jochems C, Stubelius A, Andersson A, Lagerquist MK, Ohlsson C, Carlsten H.

Arthritis Res Ther. 2011 Jun 20;13(3):R96. doi: 10.1186/ar3371.

34.

Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.

Cereda V, Vergati M, Huen NY, di Bari MG, Jochems C, Intrivici C, Gulley JL, Apelian D, Schlom J, Tsang KY.

Vaccine. 2011 Jul 12;29(31):4992-9. doi: 10.1016/j.vaccine.2011.04.101. Epub 2011 May 11.

35.

Effects of oestradiol and raloxifene on the induction and effector phases of experimental postmenopausal arthritis and secondary osteoporosis.

Jochems C, Islander U, Erlandsson M, Engdahl C, Lagerquist M, Ohlsson C, Nandakumar KS, Holmdahl R, Carlsten H.

Clin Exp Immunol. 2011 Jul;165(1):121-9. doi: 10.1111/j.1365-2249.2011.04397.x. Epub 2011 Apr 19.

36.

Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

Jochems C, Schlom J.

Exp Biol Med (Maywood). 2011 May 1;236(5):567-79. doi: 10.1258/ebm.2011.011007. Epub 2011 Apr 12. Review.

37.

Role of endogenous and exogenous female sex hormones in arthritis and osteoporosis development in B10.Q-ncf1*/* mice with collagen-induced chronic arthritis.

Jochems C, Islander U, Erlandsson M, Engdahl C, Lagerquist M, Gjertsson I, Ohlsson C, Holmdahl R, Carlsten H.

BMC Musculoskelet Disord. 2010 Dec 16;11:284. doi: 10.1186/1471-2474-11-284.

38.

Estrogens in rheumatoid arthritis; the immune system and bone.

Islander U, Jochems C, Lagerquist MK, Forsblad-d'Elia H, Carlsten H.

Mol Cell Endocrinol. 2011 Mar 15;335(1):14-29. doi: 10.1016/j.mce.2010.05.018. Epub 2010 Jun 8. Review.

PMID:
20685609
39.

Amelioration of collagen-induced arthritis and immune-associated bone loss through signaling via estrogen receptor alpha, and not estrogen receptor beta or G protein-coupled receptor 30.

Engdahl C, Jochems C, Windahl SH, Börjesson AE, Ohlsson C, Carlsten H, Lagerquist MK.

Arthritis Rheum. 2010 Feb;62(2):524-33. doi: 10.1002/art.25055.

40.

In vivo activation of gene transcription via oestrogen response elements by a raloxifene analogue.

Engdahl C, Jochems C, Gustafsson JA, van der Saag PT, Carlsten H, Lagerquist MK.

J Endocrinol. 2009 Dec;203(3):349-56. doi: 10.1677/JOE-09-0012. Epub 2009 Sep 14.

PMID:
19752149
41.

Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis.

Jochems C, Lagerquist M, Håkansson C, Ohlsson C, Carlsten H.

Clin Exp Immunol. 2008 Jun;152(3):593-7. doi: 10.1111/j.1365-2249.2008.03660.x. Epub 2008 Apr 24.

42.

Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis.

Jochems C, Islander U, Kallkopf A, Lagerquist M, Ohlsson C, Carlsten H.

Arthritis Rheum. 2007 Oct;56(10):3261-70.

43.

Identification of target cells for the genomic effects of estrogens in bone.

Windahl SH, Lagerquist MK, Andersson N, Jochems C, Kallkopf A, Håkansson C, Inzunza J, Gustafsson JA, van der Saag PT, Carlsten H, Pettersson K, Ohlsson C.

Endocrinology. 2007 Dec;148(12):5688-95. Epub 2007 Aug 30.

PMID:
17761761
44.

Estren promotes androgen phenotypes in primary lymphoid organs and submandibular glands.

Islander U, Hasséus B, Erlandsson MC, Jochems C, Skrtic SM, Lindberg M, Gustafsson JA, Ohlsson C, Carlsten H.

BMC Immunol. 2005 Jul 12;6:16.

45.

Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation.

Jochems C, Islander U, Erlandsson M, Verdrengh M, Ohlsson C, Carlsten H.

Arthritis Res Ther. 2005;7(4):R837-43. Epub 2005 Apr 27.

46.

Estren-mediated inhibition of T lymphopoiesis is estrogen receptor-independent whereas its suppression of T cell-mediated inflammation is estrogen receptor-dependent.

Islander U, Erlandsson MC, Chavoshi T, Jochems C, Movérare S, Nilsson S, Ohlsson C, Gustafsson JA, Carlsten H.

Clin Exp Immunol. 2005 Feb;139(2):210-5.

47.

Preventing and treating intertrigo in the large skin folds of adults: a literature overview.

Mistiaen P, Poot E, Hickox S, Jochems C, Wagner C.

Dermatol Nurs. 2004 Feb;16(1):43-6, 49-57. Review.

PMID:
15022504
48.

The use of fetal bovine serum: ethical or scientific problem?

Jochems CE, van der Valk JB, Stafleu FR, Baumans V.

Altern Lab Anim. 2002 Mar-Apr;30(2):219-27.

PMID:
11971757

Supplemental Content

Loading ...
Support Center